Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06442709
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-04
First Post:
2024-04-25
Brief Title:
Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients
Sponsor:
Affiliated Hospital of Nantong University
Organization:
Affiliated Hospital of Nantong University
Study Overview
Official Title:
Combined Anti-IL6R and Anticoagulation Therapy Improves Prognosis in Patients With Advanced Nasopharyngeal Carcinoma
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators have demonstrated the crucial role of the liver-lung axis in the distant metastasis of NPC Furthermore the investigators have identified a potential therapeutic approach to improve outcomes in NPC patients by identifying those most suitable for anticoagulant therapy Further the combination of anticoagulant therapy and anti-IL6R therapy has shown promising results in enhancing the prognosis of NPC patients These findings highlight the significance of targeting the liver-lung axis and utilizing personalized treatment strategies for NPC
Detailed Description:
Distant metastasis accounts for nasopharyngeal carcinoma NPC-related mortalities Recently extracellular vesicles EVs have been widely explored as key mediators of bidirectional tumor-host cell interactions by mediating pre-metastatic niche PMN formation However considering the complexity of the human body multiple organ studies of tumor metastasis remain poorly understood Here the investigators have demonstrated the crucial role of the liver-lung axis in the distant metastasis of NPC The investigators demonstrated mechanistically that hepatocellular derived EVs can be specifically taken up by the lung to form a hypercoagulable pre-metastatic microenvironment associated with IL6Furthermore the investigators have identified a potential therapeutic approach to improve outcomes in NPC patients by identifying those most suitable for anticoagulant therapy Further the combination of anticoagulant therapy and anti-IL6R therapy has shown promising results in enhancing the prognosis of NPC patients These findings highlight the significance of targeting the liver-lung axis and utilizing personalized treatment strategies for NPC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None